30
Participants
Start Date
January 31, 2004
Primary Completion Date
April 30, 2006
Study Completion Date
September 30, 2009
Docetaxel
Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
Carboplatin
Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
Oregon Health and Science University, Portland
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
Lowell General Hospital, Lowell
Wentworth Douglass Hospital, Dover
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Beth Israel Deaconess Medical Center
OTHER
Lowell General Hospital
OTHER
Massachusetts General Hospital
OTHER
Oregon Health and Science University
OTHER
Wentworth-Douglass Hospital
OTHER
Dana-Farber Cancer Institute
OTHER